What is Cormark's Forecast for Cresco Labs FY2025 Earnings?

Key Points

• Cormark has revised its FY2025 earnings estimate for Cresco Labs, lowering the expected earnings per share from ($0.07) to ($0.14), while the consensus estimate stands at ($0.20).
• Shares of Cresco Labs have been downgraded by Canaccord Genuity Group from a "strong-buy" to a "moderate buy" rating.
• Cresco Labs reported a quarterly earnings loss of ($0.05) EPS, missing the consensus estimate by one cent, while revenue for the quarter was $163.62 million.

Cresco Labs Inc. (OTCMKTS:CRLBF - Free Report) - Cormark dropped their FY2025 earnings per share estimates for shares of Cresco Labs in a note issued to investors on Monday, August 11th. Cormark analyst J. Pytlak now anticipates that the company will post earnings of ($0.14) per share for the year, down from their prior estimate of ($0.07). The consensus estimate for Cresco Labs' current full-year earnings is ($0.20) per share. Cormark also issued estimates for Cresco Labs' FY2026 earnings at ($0.06) EPS.

Separately, Canaccord Genuity Group lowered Cresco Labs from a "strong-buy" rating to a "moderate buy" rating in a research note on Tuesday, June 3rd.

Cresco Labs Price Performance

OTCMKTS CRLBF traded up $0.15 during trading hours on Wednesday, reaching $1.13. 2,968,064 shares of the stock traded hands, compared to its average volume of 778,834. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.10 and a quick ratio of 2.22. The stock has a 50 day simple moving average of $0.61 and a two-hundred day simple moving average of $0.70. Cresco Labs has a 1 year low of $0.43 and a 1 year high of $2.05. The company has a market cap of $554.85 million, a price-to-earnings ratio of -8.69 and a beta of 1.42.

Cresco Labs (OTCMKTS:CRLBF - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The company had revenue of $163.62 million for the quarter, compared to the consensus estimate of $162.00 million. Cresco Labs had a negative net margin of 6.67% and a negative return on equity of 11.77%.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.